Myomo (MYO) Stock Forecast & Price Target

Myomo is benefiting from accelerating commercialization of its MyoPro platform, with Q2 fiscal 2026 revenue of $11.7 million up 21% year over year and units sold rising to 211, while EPS of $(0.09) also beat expectations. The 2024 CMS Medicare Part B ruling materially expands reimbursement access, and the company’s shift toward the U.S. O&P channel is already showing traction, with U.S. O&P revenue up 130% in Q2 and international revenue up 32% year over year. Management’s raised 2026 revenue guidance of $45 million to $47 million, alongside a large estimated $10 billion U.S. addressable market, supports a constructive long-term growth view.

Myomo is exposed to a fragile fundamental profile because its business depends on securing and maintaining reimbursement, while directly billing insurers and relying on third-party clinical providers adds execution risk and potential fee pressure. The company also faces meaningful balance sheet and liquidity risk, which can constrain commercialization, product rollout, and operating flexibility if demand or collections weaken. Beyond that, its outlook is burdened by regulatory, competitive, and macroeconomic uncertainty, including the possibility of delayed approvals, weaker investor sentiment toward biotech/medtech names, and shifting healthcare priorities that could slow adoption.